Trimethadione

Trimethadione (Tridione) is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments.

Quick Facts Clinical data, Trade names ...

Trimethadione

Clinical data
Trade names	Tridione
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	X
Routes of administration	By mouth
ATC code	N03AC02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	High
Metabolism	Demethylated to dimethadione
Elimination half-life	12–24 hours (trimethadione) 6–13 days (dimethadione)
Excretion	Renal
Identifiers
IUPAC name 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione
CAS Number	127-48-0 Y
PubChem CID	5576
IUPHAR/BPS	7316
DrugBank	DB00347 Y
ChemSpider	5374 Y
UNII	R7GV3H6FQ4
KEGG	D00392 Y
ChEBI	CHEBI:9727
ChEMBL	ChEMBL695 Y
CompTox Dashboard (EPA)	DTXSID9021396
ECHA InfoCard	100.004.406
Chemical and physical data
Formula	C6H9NO3
Molar mass	143.142 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1N(C(=O)OC1(C)C)C
InChI InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3 Y Key:IRYJRGCIQBGHIV-UHFFFAOYSA-N Y
(verify)

Close

It is primarily effective in treating absence seizures, but can also be used in refractory temporal lobe epilepsy. It is usually administered 3 or 4 times daily, with the total daily dose ranging from 900 mg to 2.4 g. Treatment is most effective when the concentration of its active metabolite, dimethadione, is above 700 μg/mL. Severe adverse reactions are possible, including Steven Johnson syndrome, nephrotoxicity, hepatitis, aplastic anemia, neutropenia, or agranulocytosis. More common adverse effects include drowsiness, hemeralopia, and hiccups.^[1][2]